FDA Grants Priority Review for Arikayce Full Approval
2 reports, 2 independent
Updated Mon 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The U.S. Food and Drug Administration accepted the Supplemental New Drug Application (sNDA) for Arikayce, an inhalation suspension used to treat Mycobacterium avium complex (MAC) lung disease. The FDA granted Priority Review to the application, setting a target action date of January 28, 2027.
From prnewswire.com
Why it matters
Full approval could allow Arikayce to reach patients earlier in their disease course, potentially changing the treatment paradigm for MAC lung disease. Granting this approval would also fulfill a post-marketing requirement from the FDA.
From prnewswire.com
Who's involved
- FDARegulatory agency reviewing the application for Arikayce.
Keep exploring
The entities involved
Related events
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- Kevin Sabet advises on the FDA's drug policy process, which is being reported on in public hearings.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- FDA and Pfizer are seeking regulatory approval for their products.
- NRx Pharmaceuticals and TMS are undergoing various reviews with the FDA, including guidance on real-world evidence and a ketamine ANDA review.